Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VYGR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVoyager Therapeutics doubles authorized shares to 240M following stockholder approval
Filed June 10, 2026 · Period ending June 9, 2026 · ~1 min read
Key Changes
-
high
Stockholders approved doubling authorized common stock from 120 million to 240 million shares, effective immediately upon Delaware filing June 9, 2026. This provides flexibility for future capital raises, acquisitions, or equity compensation but creates potential dilution risk for existing shareholders.
Item 5.03 verify on EDGAR → -
medium
Certificate of Amendment filed with Delaware Secretary of State on June 9, 2026, making the increased share authorization immediately effective. The company can now issue up to 240 million common shares with identical rights to existing stock.
Item 5.03 verify on EDGAR → -
low
Three Class II directors elected to serve until 2029: James Geraghty, Dr. Steven Hyman, and Dr. Alfred Sandrock. All received majority support with Dr. Sandrock receiving highest approval (96% votes for).
Item 5.07 verify on EDGAR → -
low
Executive compensation approved on advisory basis with 97% stockholder support (32.0M for vs. 0.9M against), indicating shareholder satisfaction with management pay practices.
Item 5.07 verify on EDGAR → -
low
Ernst & Young LLP ratified as independent auditor for 2026 with 99.7% approval, confirming continuity in external audit relationship.
Item 5.07 verify on EDGAR →
Summary
Voyager Therapeutics has doubled its authorized common stock from 120 million to 240 million shares following stockholder approval at its 2026 Annual Meeting. The Certificate of Amendment was filed with Delaware on June 9, 2026, and became effective immediately.
This significant increase in authorized shares gives management substantial flexibility for future capital raises, potential acquisitions, or expanded equity compensation programs. For retail investors, the key concern is dilution risk. While the authorization itself doesn't issue new shares, it creates the capacity to do so without returning to shareholders for approval.
The company now has room to issue up to 240 million common shares, compared to the previous 120 million cap. This is particularly relevant for a biotech company like Voyager, which may need to raise capital to fund clinical trials and drug development. Investors should monitor upcoming SEC filings for any shelf registrations, at-the-market offerings, or other capital-raising activities that would actually issue new shares and dilute existing holdings. The company's cash position and burn rate in the next quarterly report will provide clues about whether and when management might tap this newly expanded share authorization.
Section-by-Section Diff
Event · Item 5.03 — Amendments to Articles of Incorporation or Bylaws
Voyager doubled authorized shares from 125M to 245M following stockholder approval at 2026 Annual Meeting.
Added in current filing · verify on EDGAR →
At the 2026 Annual Meeting, Voyager’s stockholders approved an amendment to Voyager’s Fifth Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”), to increase the number of authorized shares of the Company’s capital stock from 125,000,000 shares to 245,000,000 shares and to increase the number of authorized shares of Voyager’s common stock from 120,000,000 shares to 240,000,000 shares.
Voyager's stockholders approved doubling the authorized common stock from 120 million to 240 million shares, and total authorized capital stock from 125 million to 245 million shares. The amendment was filed with Delaware on June 9, 2026 and became effective immediately. The additional shares have identical rights to existing common stock.
Added in current filing · verify on EDGAR →
Voyager filed the Certificate of Amendment, which was effective upon filing, with the Secretary of State of the State of Delaware on June 9, 2026.
The Certificate of Amendment was filed with Delaware and became effective the same day as the stockholder vote. This means the increased share authorization is now in force and the company can issue up to 240 million common shares.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Voyager held its 2026 annual meeting, electing three directors, approving executive compensation, ratifying auditor, and authorizing a doubling of shares.
Added in current filing · verify on EDGAR →
Voyager’s stockholders approved an amendment to the Fifth Amended and Restated Certificate of Incorporation of Voyager Therapeutics, Inc. to increase the number of authorized shares of the Company’s capital stock from 125,000,000 shares to 245,000,000 shares and increase the number of authorized shares of common stock from 120,000,000 shares of common stock to 240,000,000 shares of common stock.
Shareholders approved doubling the authorized common stock from 120 million to 240 million shares (total capital stock from 125M to 245M). This provides flexibility for future capital raises, acquisitions, or equity compensation, but could dilute existing shareholders if new shares are issued.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Voyager’s stockholders elected James A. Geraghty, Steven Hyman, M.D., and Alfred Sandrock, M.D., Ph.D., each to serve as a Class II director until the 2029 Annual Meeting of Stockholders and until such nominee’s successor has been duly elected and qualified, subject to such nominee’s earlier death, resignation, or removal.
Three Class II directors were elected to serve three-year terms until 2029. All three nominees received majority support, with Dr. Sandrock receiving the highest approval (31.9M votes for vs. 1.2M withheld).
Event · Item 9.01 — Financial Statements and Exhibits
Voyager Therapeutics filed a certificate of amendment to its certificate of incorporation.
Added in current filing · verify on EDGAR →
Certificate of Amendment of Fifth Amended and Restated Certificate of Incorporation, of Voyager Therapeutics, Inc.
The company filed an amendment to its Fifth Amended and Restated Certificate of Incorporation.Amendments to the certificate of incorporation can involve changes to authorized shares, corporate name, governance provisions, or other fundamental corporate matters.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify